Vicarious Surgical

Phase A — Understand the business

Company Overview

Vicarious Surgical is a development-stage medical-robotics company in Waltham, MA, building a single-port surgical robot — the Vicarious Surgical System — that combines miniaturized robotics, computer science, sensing and 3D visualization to "virtually transport surgeons inside the patient" through one ~1.8 cm abdominal incision. The system's pitch: nine degrees of freedom per instrument arm (approximating a surgeon's wrist/elbow/shoulder), 28 sensors per arm for force/motion feedback, and a de-coupled architecture that keeps the robotic motion inside the abdomen rather than in large arms outside the body. First intended indication: ventral hernia repair (the filing cites ~3.9M cases worldwide, ~0.9M U.S. annually), with a claimed longer-run addressable base of ~39–45M soft-tissue abdominal/gynecological procedures.

Business model: there isn't a live one. Revenue = $0; the company "has not yet generated any revenue from operations". The intended model was a razor-and-blade capital-equipment play (sell/place the robot into hospitals and ambulatory surgical centers, then recurring instruments/service), explicitly targeting the ASC cost-sensitive segment as a wedge below Intuitive's hospital footprint. None of it was ever commercialized. Customers: none. Suppliers: third-party custom + off-the-shelf component vendors feeding in-house assembly at Waltham. Competitors: Intuitive Surgical, J&J (Ethicon/Auris/Verb), Medtronic (Covidien/Hugo), Virtual Incision, Stryker, CMR Surgical.

Corporate history is the whole story: went public 17 Sept 2021 via SPAC merger with D8 Holdings at a $1.1B combined valuation, netting the company ~$190.4M of cash (after ~$29.6M transaction costs; PIPE priced at $10.00). Nearly five years later that ~$190M — plus subsequent raises — has become a $253.4M accumulated deficit and a company voting on liquidation. This is a textbook de-SPAC deep-tech capital incineration.

Supply Chain

For a pre-commercial company the supply chain is aspirational, and its weakness was a direct cause of death. Map: custom miniaturized components + off-the-shelf parts (third-party vendors) → in-house assembly/manufacturing at the Waltham HQ → (intended) hospitals & ASCs. The company disclosed it "currently rel[ies] and expect[s] to expand on third parties for the manufacturing of certain products for preclinical and clinical testing, as well as for commercial manufacturing". No commercial supply chain was ever stood up — there is no distributor, no OEM, no installed base.

The named chokepoint is procurement of custom miniaturized robotic components: in March 2025 management blamed "material procurement issues with suppliers" for slipping the build-out and pushing first-patient timing. A robot with 28 sensors and nine-DOF miniaturized joints per arm is a bespoke-parts problem; single-source custom components on a cash-starved timeline is exactly the kind of dependency that compounds delay. The commercial-layer robotics files (kb/robotics/wiki/supply-chain.md, bottlenecks.md) frame the category's precision-actuator/sensor sourcing constraint generically; Vicarious never scaled far enough to matter within it. Bottom line: the supply chain is a liability, not a moat — it never existed at commercial scale and its immaturity helped kill the timeline.

Competitive Advantages (moats)

On paper the IP story is real: a genuinely differentiated single-incision, nine-DOF, motion-inside-the-body architecture that, if it worked and shipped, would sidestep both multi-port da Vinci's multiple incisions and da Vinci SP's larger single trocar. Founders machined the original system and the patent estate around de-coupled miniaturized actuation is the one arguably durable asset.

But a moat you cannot fund is not a moat. Judged honestly:

• Scale/brand/network effects: zero — no installed base, no surgeon-hours, no procedure data, no reputation. Intuitive's moat is 400+ peer-reviewed publications and millions of procedures on da Vinci; Vicarious has cadaver studies and animal-lab work.
• Switching costs: none — you can't lock in customers you never had.
• Bargaining power: none — a cash-starved pre-revenue microcap has zero leverage over component suppliers (who caused delays) or future hospital buyers.
• The one real asset — IP + the design itself — is now a liquidation line item, likely to be sold by an assignee for the benefit of creditors, not shareholders.

The durable truth of surgical robotics is that it is winner-take-most and brutally capital-intensive; a differentiated architecture is necessary but nowhere near sufficient. Vicarious had the architecture and ran out of the capital. Moat verdict: an interesting patent estate with no economic moat around it.

Segments

Not applicable in the revenue sense — there are no segments because there is no revenue (our figures is empty; revenue = $0). The only meaningful "segment" breakdown is the cost structure, which is where the whole story lives:

Source:. Implied G&A ≈ $16.4M FY2025.

The "improvement" is not operating leverage — it is the sound of a company being dismantled: R&D down because R&D staff were being laid off, opex down because the company was cutting to survive. Q1 2026 net loss was $7.3M vs $15.4M in Q1 2025 — again, shrinkage, not progress. There is no product mix, no geography, no accelerating line. The only trend is contraction toward zero.

---

Phase B — Measure performance (pre-revenue overlay: milestones, catalysts, runway)

Latest Result → Milestones-by-phase & the liquidity cliff

With no earnings to beat, the "result" is the cash position and the milestone state. Both are terminal.

Liquidity (the decisive number):

Source:.

Milestone state (the "pipeline"): the Vicarious System is still pre-clinical. As of the FY2025 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. the company only "plan[s] to conduct a prospective human pivotal clinical investigation under an FDA IDE" and must still complete non-clinical V&V (bench, cadaver, in-vivo animal studies) before it can even submit an IDE, let alone run the pivotal trial and then file the De Novo classification request. Translation: no IDE, no first-in-human, no design freeze. The March 2026 strategic plan still put "system design freeze by the end of 2026" as a future goal — meaning first-in-human, the pivotal trial, and De Novo submission were all still 2027+ events requiring, realistically, $100M+ of fresh capital.

Guidance/outlook: the only guidance that matters is the going-concern disclosure — cash "will be sufficient to support the Company's operations through the second quarter of 2026," raising substantial doubt about going-concern. 2026 cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits. was guided to ~$19M (cut from ~$50M mid-2025 and ~$35M late-2025). Balance-sheet flags: no traditional debt, but ~$5.7M of non-current liabilities (chiefly the Waltham operating lease); public warrants marked to $0 and delisted.

Market reaction / what was priced in: by the time of the print the market had already rendered its verdict — NYSE delisting for a sub-$15M market capMarket capitalisationThe share price multiplied by the number of shares. What the market says the equity is worth., OTC since 4 March 2026, stock at pennies. Nothing left to be surprised by.

Management commentary trend (founder→turnaround pivot)

There are no clean earnings-call transcripts on the shelf (transcripts/ empty), but the tonal arc across public commentary is unambiguous and damning:

• 2021–2023: confident de-SPAC growth narrative — build done end-2023, trials 2024, FDA De Novo 2025.
• Nov 2023: first big slip — components need more work; trials to "mid-to-late 2025," submission to "early-to-mid 2026".
• March 2025: supplier/procurement issues; first patients pushed to end-2025.
• Aug 12, 2025 (Q2 call): new CEO Stephen From takes over; first-in-human no longer in 2025; focus reduced to "design lock". The vocabulary shrank from "commercialize" to "design freeze" to, by March 2026, "pursue Nasdaq" and "reduce burn," to, by June 2026, "assignment for the benefit of creditors."

The recurring phrase they stopped saying was any firm FDA submission date; the phrase they started saying was "going concernGoing concernAn auditor’s formal doubt that the company can fund itself for the next year. It is a warning about survival, not about performance.." That is the entire sentiment trend you need.

Comps → Catalyst-context & the surgical-robotics graveyard

Multiples are meaningless for a $0-revenue dissolving shell, so the comp set is (a) the incumbent that defines the moat wall and (b) the fate of sub-scale challengers:

RBOT price ~$0.16–0.17 as of 2026-07-09. NB: one aggregator shows a $30M market cap — inconsistent with the 7.12M share count at $0.17 ($1.2M) and almost certainly stale/pre-decline; I flag the conflict and rely on the arithmetic. The takeaway is structural: surgical robotics is a category where one $140B incumbent compounds while sub-scale challengers get bought at pennies (Asensus) or dissolve (Vicarious). There is no valuation multiple to argue about — only a liquidation waterfall (Lens 11).

Stock-Price Catalysts (the 5-year death spiral)

The pattern of >5% moves reveals a market that reacted to exactly one variable: survival.

• Sept 2021: de-SPACs at ~$10 (post the 1-for-30-adjusted equivalent), ~$1.1B valuation — peak optimism.
• 2022–2023: grind lower on cash burn + first timeline slips.
• Nov 2023 / 2024: each FDA/clinical delay = a leg down; layoffs of R&D staff.
• 12 June 2024: 1-for-30 reverse stock split to hold the listing — the stock nonetheless kept falling.
• Aug 2025: CEO change + "no first-in-human in 2025" — capitulation.
• March 2026: NYSE delisting (sub-$15M cap), moves to OTC; "strategic plan" (Nasdaq/reverse split/burn cut) sparks a dead-cat bounce (52-wk high $2.20) that fully round-trips to $0.16.
• 22 June 2026: dissolution proxy — terminal.

What the market "reacts to" for this name is not earnings or product — it is each incremental signal of whether the company will run out of money. It has now answered yes.

---

Phase C — Judge people & books

Management

CEO: Stephen From (62), CEO & director since Aug 2025 — a turnaround/wind-down hire, not a robotics operator. Prior: CEO of Aruna Bio (2022–2025) and Kiora Pharmaceuticals; earlier CFO of Centelion (a Sanofi biotech subsidiary) and investment banking. Bringing in a small-cap biotech restructuring executive in Aug 2025 was, in hindsight, the board signaling that the mission had shifted from build the robot to manage the endgame.

Co-founder Adam Sachs (34) — original CEO, demoted to President when From arrived; still a director. Co-founders Sammy Khalifa (CTO) and Barry Greene built the original system. CFO: Sarah Romano (45).

• Track record: the founders built a genuinely novel robot from machined parts — real engineering achievement — but as public-company operators they missed every timeline for five straight years and never reached a human patient. Capital-allocation record: took ~$190M+ and produced $0 of revenue and a $253M deficit. That is, bluntly, one of the more complete value-destruction records in recent medtech.
• Skin in the game: founders retained super-voting Class B control throughout — Sachs held 374,635 and Khalifa 150,508 Class B shares of 653,990 total. So the people who controlled the pace of spending are the same people whose (now near-worthless) stakes track the outcome; alignment existed, competence at timeline/capital discipline did not. Khosla Ventures — a marquee tier-1 backer holding ~965k Class A shares — is taking a near-total loss.
• Founder vs professional manager: a founder-led deep-tech story that the board tried, too late, to convert to a professional-manager wind-down. The demotion of the founder-CEO 10 months before the dissolution vote tells you the board lost confidence in the original plan.

Forensic Red Flags

Accounting-fraud risk: low. Going-concern-realization risk: total. This is not a company cooking books to inflate revenue — there is no revenue to inflate. The forensic risks are the pre-revenue, wind-down kind:

• Going concern — explicitly disclosed, "substantial doubt," cash only through Q2 2026. This is the dominant flag and it is fully disclosed.
• Asset realizability — total assets of $12.6M are heavily specialized R&D equipment + prepaids that will not fetch book value in an ABC fire-sale; the board's own view is common gets ~$0 despite $3.57M book equity. Book equity ≠ recoverable value.
• SBC / dilution — historic stock-based comp flattered nothing (all losses), and the capital structure was serially diluted then reverse-split 1-for-30 (June 2024) with a second reverse split authorized (April 2026).
• Cash vs earnings — cash used in operations ($45.1M FY2025; $6.3M Q1'26) tracks the net loss closely — no aggressive accruals hiding a cash problem; the cash problem is on the surface.

Regulatory findings (required):

• SEC Litigation Releases / AAERs: None. "No LR found" and "No AAER found" for Vicarious Surgical, 2021-07-10 → 2026-07-10.
• Non-SEC (FDA/DOJ/FTC/class action): web search returned no enforcement actions, investigations, or securities class actions against the company. (No commercialized product = no FDA enforcement surface.)
• 10-K Item 3 (Legal Proceedings): "to our knowledge, we are not party to and our property is not subject to any material pending legal proceedings".
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-07-10. The risk here is insolvency, not misconduct.

---

Phase D — Project & stress-test (special-situation overlay: liquidation, not EPS)

Forward "Projection" → Liquidation-waterfall / recovery analysis

There is no EPS to forecast (no revenue, no path to profit, dissolving). The only defensible projection is the recovery to common in the ABC/dissolution. No our model logged — a Brier EPS forecast is meaningless here (per --watchlist rules, no forecast create).

Waterfall (as of 31 Mar 2026, the balance sheet the proxy relies on):

• Total assets: $12.586M (of which liquid cash + STI only $3.682M; the rest is specialized equipment, prepaids, right-of-use lease asset — low fire-sale recovery).
• Total liabilities: $9.016M (current $3.35M + ~$5.7M non-current, mainly the Waltham lease).
• Book equity: $3.57M — but the board states that "based upon our current outstanding liabilities it is unlikely you will receive any distribution".

Why book equity ≈ $3.57M still maps to ~$0 for common: (1) non-cash assets liquidate well below carrying value in an ABC; (2) continued Q2 burn (~$1.5–2M) further drains the $3.68M before the process even completes; (3) ABC/assignee/wind-down professional fees are senior to equity; (4) the lease and accrued liabilities absorb realizable proceeds. Base / Bull / Bear:

• Base: common recovery ~$0.00–$0.02/share; equity is effectively a zero.
• Bear: $0.00 — assignee proceeds fully consumed by creditors + fees.
• Bull: a low-probability tail where a strategic buyer pays for the IP/patents above liabilities at the eleventh hour (the Asensus/Karl Storz analog — but that was $0.35/share, and it required a willing acquirer Vicarious explicitly says it failed to find). Even the bull case is pennies, and it is contradicted by the board's disclosed failure to find a buyer.

The decisive question the asks — "does cash runway reach the next value-inflection catalyst?" — answers itself: NO, by years and by ~$100M. The runway ran out one full De Novo pathway before the first catalyst.

Bull vs Bear

Bull case (steelmanned, for completeness): A genuinely novel single-port, nine-DOF architecture addressing a 39–45M-procedure TAM, in a category where the one incumbent trades at ~$142B and ~50x EBITDA — i.e., the prize is enormous and the technology is differentiated. If (huge if) an acquirer valued the IP/design and hired the team, the patents could live on inside a Medtronic/J&J/Stryker. But this is an asset bull case, not an equity bull case — and it accrues to creditors and an acquirer, not to RBOT shareholders.

Bear case (the reality): three permanent impairments, all already realized: (1) capital exhaustion — $3.68M against a >$100M path to approval; (2) no market access — delisted to OTC, no ability to raise equity on acceptable terms, explicitly failed to find debt/equity/buyer; (3) terminal governance decision — the board has chosen dissolution over continuing. Pre-mortem (it's 18 months out and the thesis broke): it already broke — the "thesis" died the moment the July 21 vote is cast; there is no 18-month scenario, only a wind-down. Multiples too high? There is no multiple; there is a liquidation. Contrarian view of what the market refuses to see: nothing — for once the market (pennies, delisted) sees this exactly right. The only "refusal to see" would be a retail buyer treating $0.17 as cheap; it is not cheap, it is a claim junior to $9M of liabilities the board says will consume the estate.

Devil's Advocate (short-seller)

As a short-seller there is nothing left to dismantle — the bull case has already been dismantled by the issuer itself. The structural break in how the company "makes money" is that it never did and now never will. Revenue concentration risk is moot (revenue is $0). The moat is weaker than any bull thinks because it was never funded to exist. The most dangerous competitor was never Intuitive — it was the calendar and the cash balance, and both won. The worst capital-allocation move was the entire arc: ~$190M+ of SPAC/PIPE capital spent over ~5 years reaching not even first-in-human. The assumptions that had to hold for the price — continued financing access, a completable design, a reachable FDA path — all failed simultaneously. The single scenario that permanently impairs the business (insolvency) is not a scenario; it is the current, disclosed state. The only short-seller caution is mechanical: at $0.16 and ~$1.2M market cap the borrow is nonexistent and the downside to a hard-zero is only pennies — there is no trade here, long or short; there is only avoidance.

Management Questions (ordered by information value)

1. What is the assignee's realistic estimate of gross liquidation proceeds for the IP, equipment, and lease, and the resulting recovery to unsecured creditors vs. common? (The one number that decides whether $0.17 is a zero.)
2. Did any party submit a bid for the whole company or the IP above outstanding liabilities during the sale process, and at what price? (Tests the only bull tail.)
3. What are the total expected ABC + wind-down professional fees, and where do they rank in the waterfall vs. the lease and accrued liabilities?
4. What is the status and disposition plan for the patent estate — sold as part of the ABC, or abandoned? Who are the interested strategics?
5. Why ABC over Chapter 7/11, specifically — what recovery delta and which creditor classes benefit?
6. What is the current monthly cash burn post the March 2026 headcount cut, and the exact projected cash-zero date?
7. Were there change-of-control, retention, or severance payments to executives/directors triggered by the wind-down, and how senior are they in the waterfall?
8. What became of the $3M H.C. Wainwright ATM (Dec 2025) — why was it never drawn even as insolvency approached?
9. Are there outstanding warrant or contingent liabilities (Private Placement Warrants) that could dilute or rank ahead of common in a residual scenario?
10. What contractual obligations survive dissolution (lease guarantees, D&O tail, indemnifications)?
11. Was a reverse merger / shell-preservation alternative evaluated, and why rejected in favor of dissolution? (Some OTC shells retain value as a listing vehicle.)
12. What milestones would have been required to make the company financeable, and how far short did design-freeze progress fall?
13. What is the plan for clinical/regulatory data and trade secrets — transferred to a buyer, or lost?
14. What fiduciary process did the board follow to conclude common recovery is ~$0, and what independent advice supported it?
15. For the founders holding super-voting Class B: how are you voting the dissolution, and what does that signal about any residual-value belief?

---